A novel Phase 2 double-blind randomized controlled clinical trial to evaluate the efficacy of centrally acting non-toxic ACE inhibition in cognitive impairment associated with SLE

Go Back to All Clinical Trials

A novel Phase 2 double-blind randomized controlled clinical trial to evaluate the efficacy of centrally acting non-toxic ACE inhibition in cognitive impairment associated with SLE

Brief description of study

This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function in lupus patients with elevated resting metabolism on a screening FDG-PET scan performed prior to study enrollment. The researchers will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory and concentration).

Clinical Study Identifier: s19-01858

ClinicalTrials.gov Identifier: NCT04486118

Principal Investigator: Amit Saxena.

Other Investigators: Howard Belmont, Fardina Malik, Janine M. Sullivan, Michael Toprover.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies